Shares of Corvus Pharmaceuticals Inc. (CRVS), a clinical-stage biopharmaceutical company, touched a new 52-week high of $4.35 yesterday, as the company gears up for data announcement regarding its lead drug candidate, Soquelitinib, in the coming months.
Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells, and plays a role in T cell and natural killer (NK) cell immune function.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com